RCUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-08), the Trailing Annual Dividend Yield of Arcus Biosciences is 0.00%.
The historical rank and industry rank for Arcus Biosciences's Dividend Yield % or its related term are showing as below:
Arcus Biosciences's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.
As of today (2024-06-08), the Forward Dividend Yield % of Arcus Biosciences is 0.00%.
Arcus Biosciences's Dividends per Share for the three months ended in Mar. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
The historical data trend for Arcus Biosciences's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Arcus Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Arcus Biosciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Arcus Biosciences (NYSE:RCUS) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Arcus Biosciences's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Goeltz Ii Robert C. | officer: Chief Financial Officer | 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080 |
Juan C. Jaen | director, 10 percent owner, officer: President | 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Jennifer Jarrett | officer: See Remarks | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Alexander Azoy | officer: Chief Accounting Officer | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Terry J Rosen | director, 10 percent owner, officer: Chief Executive Officer | C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080 |
Carolyn C. Tang | officer: General Counsel | 3928 POINT EDEN WAY, HAYWARD CA 94545 |
Dimitry Sa Nuyten | officer: Chief Medical Officer | 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710 |
Linda Slanec Higgins | director | 3610 LOUIS RD., PALO ALTO CA 94303 |
Nicole Lambert | director | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
William Grossman | officer: Chief Medical Officer | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Yasunori Kaneko | director, 10 percent owner | 509 ROEHAMPTON, HILLS BOROUGH CA 94010 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Michael Quigley | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew J Perlman | director | 618 MIRADA AVE, STANFORD CA 94305 |
From GuruFocus
By Business Wire • 11-14-2023
By Business Wire Business Wire • 05-08-2023
By Business Wire • 12-11-2023
By Business Wire • 10-10-2023
By Business Wire Business Wire • 05-15-2023
By Business Wire • 06-26-2023
By Business Wire • 09-11-2023
By Business Wire • 01-16-2024
By Business Wire Business Wire • 03-02-2023
By Business Wire Business Wire • 06-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.